Literature DB >> 6436485

Impaired glycine-serine conversion and increased plasma taurine levels in episodic psychotic patients with psychedelic symptoms.

J Bruinvels, L Pepplinkhuizen.   

Abstract

A disturbance of serine-glycine metabolism has been demonstrated in patients suffering from episodic acute psychosis, characterized by sensory perceptual distortions in whom oral loading with either serine or glycine induced psychedelic symptoms. Fasting plasma amino acid levels in oral serine-responsive patients were compared with those in glycine-responsive and manic-depressive patients. Only serine-responsive patients had a decreased plasma serine and increased plasma taurine concentration, while glycine responsive patients showed decreased alanine and manic-depressive patients an increased plasma glycine level. Amino acid analyses of plasma samples obtained after serine loading in patients and controls suggest that serine-responsive patients had an impaired conversion of glycine into serine. The results suggest that the higher plasma taurine level in serine-responsive patients is caused by an increased synthesis of taurine from homocysteine and serine. The limiting capacity of methyltetrahydrofolate-homocysteine methyltransferase coupled to increased formation of taurine may be responsible for the serine-evoked psychotic syndrome.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6436485     DOI: 10.1016/0022-3956(84)90021-9

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  2 in total

1.  Homozygous thermolabile methylenetetrahydrofolate reductase in schizophrenia-like psychosis.

Authors:  B Regland; T Germgård; C G Gottfries; B Grenfeldt; A C Koch-Schmidt
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

2.  Serotoninergic status in patients with hereditary vascular retinopathy syndrome.

Authors:  C W Storimans; D Fekkes; A van Dalen; E D Bleeker-Wagemakers; J A Oosterhuis
Journal:  Br J Ophthalmol       Date:  1998-08       Impact factor: 4.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.